Absci Corp

  • Health Care
  • Biotechnology: Commercial Physical & Biological Resarch
  • www.absci.com
  • Moat Score
  • Safety Score
  • Market Cap $338.54M
  • PE -3
  • Debt $2.54M
  • Cash $64.13M
  • EV $276.95M
  • FCF -$76.81M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$107.48M
EBIT-$107.42M
ROE-54%
ROA-46%
FCF-$76.81M
Equity$198.80M
Growth Stability1
PE-3.15
PB1.7
P/FCF-4.41
P/S70.31
Price/Cash0.19
Debt/Equity0.01
Debt/FCF-0.03
Net Margins-2K%
Op. Margins-2K%
Sales Growth YoY31%
Sales Growth QoQ77%
Sales CAGR-5%
Equity CAGR-17%
Earnings Growth YoY20%
Earnings Growth QoQ-9%
Sales CAGR 5Y-5%
Equity CAGR 5Y-18%
Earnings CAGR 3Y-12%
Sales CAGR 3Y-12%
Equity CAGR 3Y-16%
Market Cap$338.54M
Revenue$4.82M
Assets$232.45M
Total Debt$2.54M
Cash$64.13M
Shares Outstanding124.46M
EV276.95M
Moat Score1%
Safety Score65%
Working Capital128.7M
Current Ratio5.72
Shares Growth 3y11%
Equity Growth QoQ11%
Equity Growth YoY-17%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

SEC Filings

Direct access to Absci Corp (ABSI) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2025
    • 10-Q Mar 31
  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Absci Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Absci Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Absci Corp Discounted Cash Flow

Fully customizable DCF calculator online for Absci Corp.

= -$768M
012345678910TV
fcf-$77M-$77M-$77M-$77M-$77M-$77M-$77M-$77M-$77M-$77M-$77M-$768M
DCF-$70M-$63M-$58M-$52M-$48M-$43M-$39M-$36M-$33M-$30M-$296M
Value-$768M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/202012/202112/202212/202312/2024TTM
Net Margins-1K%-2K%-2K%-2K%-2K%-2K%
ROA--18%-33%-50%-48%-46%
ROE--28%-38%-63%-58%-54%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/202012/202112/202212/202312/2024TTM
Debt over FCF--0.06-0.16-0.18-0.1-0.03
Debt over Equity-0.010.020.060.070.040.01
Growth Stability-----1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-0%20%-1%-21%-5%
Earnings YoY growth-109%2%5%-7%-
Equity YoY growth--509%-25%-36%2%-18%
FCF YoY growth-650%-1%-33%11%-